Search Results

You are looking at 31 - 40 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

of septic shock diagnosis, maximum SOFA score during the ICU stay, length of stay (pre-ICU, ICU, hospital), neutropenia (absolute neutrophil count [ANC] ≤1,500/mm 3 ), severe neutropenia (ANC <500/mm 3 ), therapeutic interventions during the ICU stay

Full access

Controversies Regarding Use of Myeloid Growth Factors in Leukemia

Jacqueline N. Poston and Pamela S. Becker

Acute Myeloid Leukemia The 2 key goals of myeloid growth factor (MGF) use in the management of acute myeloid leukemia (AML) have been (1) a theoretical benefit for “priming” to improve efficacy of chemotherapy, and (2) reduction of neutropenia

Full access

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Featured Updates to the NCCN Guidelines

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino

filgrastim and pegfilgrastim, are primarily used to reduce the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of many chemotherapy regimens. Patients

Full access

Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 11 Trillet-Lenoir V Green J Manegold C

Full access

Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Counterpoint

Johan Maertens, Kristel Buvé, and Elias Anaissie

meta-analysis of randomised-controlled trials . Br J Haematol 2005 ; 131 : 22 – 28 . 7. Cornely OA Maertens J Winston DJ . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia . N Engl J Med 2007 ; 356

Full access

Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Point

Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis, and Brahm H. Segal

; 34 : 7 – 14 . 2. Segal BH Almyroudis NG Battiwalla M . Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal

Full access

Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy

Gary H. Lyman and Jessica Malone Kleiner

– 454 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymph 2003 ; 44 : 2069 – 2076 . 3. Lyman GH . Guidelines of

Full access

Myeloid Growth Factors

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong

: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440 – 454 . 2 Dale DC . Colony-stimulating factors for the management of neutropenia in cancer patients . Drugs 2002 ; 62 ( Suppl 1 ): 1 – 15 . 3

Full access

Growth Factors in Leukemia

Olga Frankfurt and Martin S. Tallman

; 11 : 466 – 478 . 3. Lieschke GJ Grail D Hodgson G . Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization . Blood 1994

Full access

HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

.2%–55.8%), vomiting (33.7%, 29.5%–38.3%), neutropenia (24.7%, 15.3%–37.4%), headache (23.9%, 19.9%–28.4%), and reduced appetite (21.7%, 19.3%–24.3%). Myeloid neoplasms were rare (1.2%, 0.7%–1.9%). Incidence of grade 3 or higher AE was 44.3% (30.2%–59.5%) and often